STERIS plc (NYSE:STE) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC trimmed its position in shares of STERIS plc (NYSE:STE - Free Report) by 13.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,688 shares of the medical equipment provider's stock after selling 7,139 shares during the quarter. Segall Bryant & Hamill LLC's holdings in STERIS were worth $10,129,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Grove Bank & Trust increased its holdings in STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 142 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of STERIS during the 1st quarter valued at about $43,000. Golden State Wealth Management LLC increased its stake in shares of STERIS by 503.0% in the 1st quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 166 shares in the last quarter. Wayfinding Financial LLC acquired a new position in STERIS in the 1st quarter worth about $46,000. Finally, Brown Brothers Harriman & Co. grew its holdings in STERIS by 66.7% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 88 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other STERIS news, CEO Daniel A. Carestio sold 17,626 shares of STERIS stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $242.56, for a total value of $4,275,362.56. Following the sale, the chief executive officer owned 51,385 shares in the company, valued at $12,463,945.60. The trade was a 25.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Cary L. Majors sold 12,828 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total value of $3,208,026.24. Following the transaction, the senior vice president owned 11,372 shares of the company's stock, valued at approximately $2,843,909.76. This represents a 53.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a report on Monday, April 7th. Stephens reissued an "overweight" rating and set a $250.00 target price on shares of STERIS in a research note on Thursday, May 15th. JMP Securities raised their price target on shares of STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a research note on Friday, May 16th. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 14th. Finally, Morgan Stanley raised STERIS from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $260.00 to $276.00 in a report on Tuesday. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, STERIS currently has a consensus rating of "Moderate Buy" and an average price target of $266.50.

STERIS Price Performance

NYSE STE traded up $0.82 during trading hours on Friday, hitting $225.41. 1,721,770 shares of the company's stock traded hands, compared to its average volume of 563,743. The company has a market capitalization of $22.17 billion, a PE ratio of 36.36 and a beta of 0.92. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.96 and a quick ratio of 1.39. STERIS plc has a 52-week low of $200.98 and a 52-week high of $252.79. The firm's 50-day moving average is $238.70 and its 200-day moving average is $226.55.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.15. STERIS had a return on equity of 14.21% and a net margin of 11.26%. The business had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.47 billion. During the same period in the prior year, the business earned $2.58 earnings per share. The business's revenue was up 5.7% compared to the same quarter last year. Equities analysts forecast that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 26th. Stockholders of record on Tuesday, June 10th were issued a dividend of $0.57 per share. The ex-dividend date was Tuesday, June 10th. This represents a $2.28 annualized dividend and a dividend yield of 1.01%. STERIS's dividend payout ratio is presently 36.77%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.